protocolSection identificationModule nctId: NCT06351657, orgStudyIdInfo id: 1088/2024, briefTitle: Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression, acronym: APENNINES, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2027-07, completionDateStruct date: 2027-07, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Medical University of Vienna, class: OTHER, collaborators name: University Medical Centre Ljubljana, collaborators name: Centre Hospitalier Universitaire Dijon, collaborators name: University of Zurich, collaborators name: Vista Klinik, collaborators name: Queen's University, Belfast, collaborators name: Fundacion Clinic per a la Recerca Biomédica, descriptionModule briefSummary: The goal of this prospective, multinational, multicenter observational study is to assess and predict progression in non-foveal, non-vision compromising atrophic AMD on an individual-based level over two years. The main objectives of this study are:* Assess the individual progression rate of a patient in non-foveal, non-vision compromising atrophic AMD and assess personalized risk of progression based on imaging.* Identify and quantify focal and global alterations in the retina in regard to disease progression.* Evaluate the monitoring of AMD progression using approved AI algorithms.All patients will be followed for 24 months with 6 month intervals to assess clinical changes. Monitoring of disease progression will be performed using the following routine in-vivo imaging procedures:* Scanning Laser Fundus Photography* Color Fundus Photography (CFP)* Optical Coherence Tomography (OCT)* Optical Coherence Tomography Angiography (OCTA)Patients will be asked for their medical history. Standard ophthalmic examination, as well as a questionnaire on visual function will be carried out.No intervention will be performed during the study since no treatment is yet available within Europe. As soon as treatment is approved in the EU, patients in this cohort might receive treatment according to availability in their respective country and standard of care. If treatment will be performed, it will be as standard of care outside the study according to each country's standard of care and by EMA label., conditionsModule conditions: Age-Related Macular Degeneration, conditions: Geographic Atrophy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, outcomesModule primaryOutcomes measure: To characterise and quantify focal and global changes of the retina by retinal imaging to identify patients at risk for fast geographic atrophy (GA) progression, secondaryOutcomes measure: To identify and quantify disease progression-related biomarkers, secondaryOutcomes measure: To evaluate monitoring AMD progression using approved AI algorithms., eligibilityModule sex: ALL, minimumAge: 55 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False